

ASX/Media Release
26 October 2021
Results of Annual General Meeting

Perth 26 October 2021: Medical dermatology company Botanix Pharmaceuticals Limited (“Botanix” or the “Company”) advises that the Annual General Meeting of the Company was held today, 26 October 2021. All resolutions put to the meeting were passed on a Poll. In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, the Company advises that details of the Poll results and the proxies received in respect of each resolution are set out below:

Poll Results

Resolutions		For		Against		Abstain
		Number	%	Number	%	Number
1	Adoption of Remuneration Report (non-binding)	67,070,973	91.52	6,213,965	8.48	924,910
2	Re-election of Director –Dr William Bosch	157,634,687	98.27	2,771,908	1.73	541,560
3	Approval of Additional 10% Placement Capacity	152,726,637	95.38	7,392,615	4.62	828,903
4	Botanix pharmaceuticals Limited Employee Securities Incentive Plan	70,292,744	95.92	2,988,931	4.08	928,173
5	Renewal of proportional takeover provisions in Constitution	158,933,977	99.16	1,339,875	0.84	674,303

Summary of Proxy Votes Received

Resolutions		For	Against	At Proxy Holders Discretion	Abstain
1	Adoption of Remuneration Report (non-binding)	64,616,109	6,213,965	1,736,514	924,910
2	Re-election of Director Dr William Bosch	155,192,932	2,771,908	1,723,405	541,560
3	Approval of Additional 10% Placement Capacity	150,165,773	7,392,615	1,842,514	828,903
4	Botanix pharmaceuticals Limited Employee Securities Incentive Plan	67,840,010	2,988,931	1,734,384	928,173
5	Renewal of proportional takeover provisions in Constitution	156,446,222	1,339,875	1,769,405	674,303

Release authorised by

Simon Robertson

Company Secretary

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited (ASX:BOT) is a clinical stage dermatology company based in Perth (Australia) and Philadelphia (USA) committed to the development of pharmaceutical products that are underpinned by science and supported by well-controlled randomised clinical trials. The Company has two complimentary development platforms - dermatology and antimicrobial products - both of which currently leverage the unique anti-inflammatory, immune modulating and antimicrobial properties of cannabinoids, particularly synthetic cannabidiol or CBD. Botanix has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases, which it utilises in its existing development programs and is being explored with a view to being utilized in a number of other product opportunities.

The Company is developing a pipeline of product candidates with recent positive data from its BTX 1801 Phase 2a antimicrobial study and its Phase 1b/2a rosacea clinical study is currently enrolling patients. Following a successful meeting with the FDA, the Company has also confirmed a drug development plan for the BTX 1503 acne Phase 3 program to support registration. In addition, Botanix plans to advance its BTX 1204A atop dermatitis program to a proof of concept canine study in Q3 CY2021 following encouraging early data from a recent pilot study. To learn more please visit: <http://www.botanixpharma.com/>

For more information, please contact:

General enquiries

Corporate Communications

Botanix Pharmaceuticals

P: +61 8 6555 2945

investors@botanixpharma.com

Investor enquiries

Hannah Howlett

WE Communications

P: +61 450 648 064

hhowlett@we-worldwide.com

Media enquiries

Haley Chartres

HACK

P: +61 423 139 163

haley@hck.digital

Cautionary Note on Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The

Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.